Exact Sciences has projected 2024 total revenues of between $2.73bn and $2.75bn, down from guidance of $2.81bn to $2.85bn posted in its third-quarter earnings report. Full-year 2023 revenues for the cancer screening and test manufacturer were £2.5bn.
“The biggest factor is historically we have seen a big ramp up in our orders in late August through to November, directly tied to physician and wellness visits,” said Aaron
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?